Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

Zhuhai Beihai Biotech’s Beizary Receives FDA Clearance for Multiple Cancer Indications

Fineline Cube Oct 28, 2024

Zhuhai Beihai Biotech Co., Ltd has announced that it has received marketing clearance from the...

Company Drug

BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option

Fineline Cube Oct 28, 2024

BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced...

Company Drug

RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment

Fineline Cube Oct 28, 2024

RemeGen (HKG: 9995), a China-based pharmaceutical company, has announced that the Center for Drug Evaluation...

Policy / Regulatory

China’s Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports

Fineline Cube Oct 28, 2024

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Drug

RemeGen’s Taitaxipu Receives CDE Acceptance for New Indication Application in China

Fineline Cube Oct 27, 2024

RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced that the Center for Drug Evaluation...

Company Medical Device

Shanghai MicroPort Initiates Pre-Marketing Clinical Study for Embolic Microspheres in Liver Cancer Treatment

Fineline Cube Oct 26, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced...

Company Drug

Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center

Fineline Cube Oct 26, 2024

On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration...

Company

TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs

Fineline Cube Oct 26, 2024

TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million...

Policy / Regulatory

Jiangxi Province to Implement Direct Medical Insurance Fund Payments for NRDL Drugs from December 2024

Fineline Cube Oct 25, 2024

The Jiangxi Province Healthcare Security Administration and the Jiangxi Provincial Department of Finance have jointly...

Company Drug

BMS Launches Cardiac Myosin Inhibitor Camzyos in China for Obstructive Hypertrophic Cardiomyopathy

Fineline Cube Oct 25, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin...

Company

Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion

Fineline Cube Oct 25, 2024

Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced...

Company

Hengrui Pharmaceuticals Considers HKEX Secondary Listing Amid Financing Challenges in Mainland China

Fineline Cube Oct 25, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, is reportedly planning...

Company Drug

Everest Medicines’ Velsipity Approved for Use in Select Hospitals in China’s Greater Bay Area

Fineline Cube Oct 25, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

Daiichi Sankyo’s Pexidartinib Poised for Priority Review in China for TGCT Treatment

Fineline Cube Oct 25, 2024

The official website of the Center for Drug Evaluation (CDE) under China’s National Medical Products...

Company Deals

AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets

Fineline Cube Oct 25, 2024

AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing...

Company Drug

Asieris Pharmaceuticals Gets FDA Green Light for USP1 Inhibitor APL-2302 in Advanced Solid Tumors

Fineline Cube Oct 25, 2024

Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has announced that it...

Company Drug

Henlius Biotech Commences Global Phase III Trial for Serplulimab in First-Line Metastatic Colorectal Cancer

Fineline Cube Oct 25, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Drug

ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Dual-Target Therapy in Systemic Lupus Erythematosus

Fineline Cube Oct 25, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a Chinese biopharmaceutical company, has announced the first...

Policy / Regulatory

China’s NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding

Fineline Cube Oct 25, 2024

The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding...

Company Drug

Sanofi’s Dupixent Demonstrates Positive Results in Phase III Study for Chronic Urticaria

Fineline Cube Oct 25, 2024

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced the presentation of new data from...

Posts pagination

1 … 330 331 332 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.